Literature DB >> 21944156

Fertility-sparing management of endometrial adenocarcinoma.

Jessie Dorais1, Mark Dodson, Jacob Calvert, Benjamin Mize, Jennifer Mitchell Travarelli, Kory Jasperson, Charles Matthew Peterson, Andrew P Soisson.   

Abstract

UNLABELLED: Approximately 15% of patients with endometrial cancer are premenopausal. Previous studies largely support the conservative treatment of endometrial cancer in women desiring future fertility. From these studies, 75% to 80% of patients demonstrate a complete response to progestin therapy and the average recurrence rate is 30% to 35%. Conservative therapy should be reserved for women with International Federation of Gynecology and Obstetrics grade I tumors. Before conservative management, patients should be informed of the elevated risk (11%-29%) of concurrent ovarian cancer in cases of premenopausal endometrial cancer, and screening and ongoing surveillance during the treatment period is mandatory. A suggestion of myometrial invasion or metastatic disease is a contraindication to conservative management. Individuals meeting criteria for Lynch syndrome testing should be referred to genetic counseling. Fertility treatment should be individualized, and close surveillance is required during treatment. Staging hysterectomy is recommended after the completion of the childbearing period. TARGET AUDIENCE: Obstetricians & Gynecologists, Family Physicians Learning
Objectives: After participating in this activity, physicians should be better able to select appropriate candidates with endometrial cancer for fertility-sparing treatment. Educate patients with endometrial cancer regarding the risks and benefits of standard of care therapy and conservative therapy and screen appropriate patients for Lynch syndrome.

Entities:  

Mesh:

Year:  2011        PMID: 21944156     DOI: 10.1097/OGX.0b013e31822f8f66

Source DB:  PubMed          Journal:  Obstet Gynecol Surv        ISSN: 0029-7828            Impact factor:   2.347


  8 in total

1.  Imiquimod Induces Apoptosis in Human Endometrial Cancer Cells In vitro and Prevents Tumor Progression In vivo.

Authors:  Aliyah Almomen; Elke A Jarboe; Mark K Dodson; C Matthew Peterson; Shawn C Owen; Margit M Janát-Amsbury
Journal:  Pharm Res       Date:  2016-05-31       Impact factor: 4.200

2.  Oncofertility in Canada: gonadal protection and fertility-sparing strategies.

Authors:  R Ronn; H E G Holzer
Journal:  Curr Oncol       Date:  2013-12       Impact factor: 3.677

Review 3.  Progestins in the fertility-sparing treatment and retreatment of patients with primary and recurrent endometrial cancer.

Authors:  Jeong-Yeol Park; Joo-Hyun Nam
Journal:  Oncologist       Date:  2015-02-11

4.  Fertility sparing treatment in young patients with early endometrial adenocarcinoma: case series.

Authors:  Mehri Jafari Shobeiri; Parvin Mostafa Gharabaghi; Heidarali Esmaeili; Elaheh Ouladsahebmadarek; Mahzad Mehrzad-Sadagiani
Journal:  Pak J Med Sci       Date:  2013-04       Impact factor: 1.088

Review 5.  Fertility preservation in female cancer patients: An overview.

Authors:  Nalini Mahajan
Journal:  J Hum Reprod Sci       Date:  2015 Jan-Mar

6.  Fertility-preserving treatment in complex atypical hyperplasia and early endometrial cancer in young women with oral progestin: Is it effective?

Authors:  Ji Sun Baek; Wan Ho Lee; Woo Dae Kang; Seok Mo Kim
Journal:  Obstet Gynecol Sci       Date:  2016-01-15

7.  Polycystic Ovarian Morphology may be a Positive Prognostic Factor in Patients with Endometrial Cancer who Achieved Complete Remission after Fertility-Sparing Therapy with Progestin

Authors:  Yamato Fukui; Ayumi Taguchi; Katsuyuki Adachi; Marie Sato; Akira Kawata; Michihiro Tanikawa; Kenbun Sone; Mayuyo Mori; Kazunori Nagasaka; Yoko Matsumoto; Takahide Arimoto; Katsutoshi Oda; Yutaka Osuga; Tomoyuki Fujii
Journal:  Asian Pac J Cancer Prev       Date:  2017-11-26

8.  Endometrial cancer in an increasingly obese population: Exploring alternative options when surgery may not cut it.

Authors:  Jeanine N Staples; Lisa Rauh; M Sean Peach; William D Baker; Susan C Modesitt
Journal:  Gynecol Oncol Rep       Date:  2018-04-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.